Marshall Wace, LLP Sellas Life Sciences Group, Inc. Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.18 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$754,1430.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$574,9310.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$408,8490.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$293,0423.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $19.5M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...